Suppr超能文献

凝血因子XIII活性降低患者接受凝血因子XIII治疗联合确定性手术治疗多发难治性肠皮肤瘘的疗效

Efficacy of administration of coagulation factor XIII with definitive surgery for multiple intractable enterocutaneous fistulae in a patient with decreased factor XIII activity.

作者信息

Saigusa Susumu, Yamamura Takeshi, Tanaka Koji, Ohi Masaki, Kawamoto Aya, Kobayashi Minako, Inoue Yasuhiro, Kusunoki Masato

机构信息

Department of Gastrointestinal and Pediatric Surgery, Division of Reparative Medicine, Institute of Life Sciences, Mie University Graduate School of Medicine, Tsu, Japan.

出版信息

BMJ Case Rep. 2011 Mar 15;2011:bcr0920103342. doi: 10.1136/bcr.09.2010.3342.

Abstract

Enterocutaneous fistulae (ECF) are challenging problem commonly encountered by surgeons and cause significant complications. They not only prolong hospital stay, but also restrict a patient's activities of daily living. The authors report a case of successful treatment of multiple intractable ECF in a patient with decreased coagulation factor XIII (FXIII) activity using intravenous FXIII treatment. A 74-year-old man with multiple ECF was referred. Although no factors involved in impaired wound were initially identified, he developed ECF after multiple surgical interventions with repeated wound dehiscence. FXIII activity was below the normal value. A definitive operation was performed and FXIII was administrated for 5 days postoperatively. There was no fistula recurrence and no other complications. Preoperative assessment of factors related to wound repair, such as FXIII activity, may be important for patients with wound dehiscence and subsequent fistula development and should be considered in patients who are resistant to standard treatments.

摘要

肠皮肤瘘(ECF)是外科医生常遇到的具有挑战性的问题,并会引发严重并发症。它们不仅延长住院时间,还会限制患者的日常生活活动。作者报告了1例使用静脉注射凝血因子 XIII(FXIII)治疗成功治愈1例凝血因子 XIII(FXIII)活性降低患者的多发顽固性ECF的病例。 一名患有多发ECF的74岁男性前来就诊。虽然最初未发现伤口愈合受损的相关因素,但他在多次手术干预且伤口反复裂开后出现了ECF。FXIII活性低于正常值。进行了确定性手术,并在术后给予FXIII治疗5天。未出现瘘复发及其他并发症。术前评估与伤口修复相关的因素,如FXIII活性,对于有伤口裂开及随后发生瘘的患者可能很重要,对于对标准治疗耐药的患者也应予以考虑。

相似文献

8
New developments in the area of factor XIII.因子 XIII 领域的新进展。
J Thromb Haemost. 2013 Feb;11(2):234-44. doi: 10.1111/jth.12074.

本文引用的文献

3
Enterocutaneous fistula: are treatments improving?肠皮肤瘘:治疗方法是否在改善?
Surgery. 2006 Oct;140(4):570-6; discussion 576-8. doi: 10.1016/j.surg.2006.07.003. Epub 2006 Sep 6.
5
Nutrition and management of enterocutaneous fistula.肠外瘘的营养与管理
Br J Surg. 2006 Sep;93(9):1045-55. doi: 10.1002/bjs.5396.
6
Factor XIII therapy of anastomotic leak, and circulating growth factors.
J Nippon Med Sch. 2006 Feb;73(1):18-23. doi: 10.1272/jnms.73.18.
7
Current management of enterocutaneous fistula.肠皮肤瘘的当前管理
J Gastrointest Surg. 2006 Mar;10(3):455-64. doi: 10.1016/j.gassur.2005.08.001.
8
Factor XIII (FXIII) and angiogenesis.凝血因子 XIII(FXIII)与血管生成。
J Thromb Haemost. 2006 Jan;4(1):19-25. doi: 10.1111/j.1538-7836.2005.01473.x. Epub 2005 Aug 26.
9
An 11-year experience of enterocutaneous fistula.肠皮肤瘘的11年经验。
Br J Surg. 2004 Dec;91(12):1646-51. doi: 10.1002/bjs.4788.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验